Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur EDOUARD PERTUISET

RPPS 10003976239
📊 Reconnaissance scientifique : 31/100📝 130 articles publiés📚 HAL (8)

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

  • CES Rhumatologie

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

31

h articles cités ≥ h fois chacun. Un h de 31 = 31 publications avec 31+ citations.

Citations

4 799

Publications

130

i10-index

51

Thématiques principales

  • Rheumatoid Arthritis Research and Therapies ×35
  • Spondyloarthritis Studies and Treatments ×26
  • Orthopedic Infections and Treatments ×22
  • Infectious Diseases and Tuberculosis ×21
  • Hematological disorders and diagnostics ×17

Affiliations FR : BP (France) · Centre Hospitalier René-Dubos

Voir sur OpenAlex ↗

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2005

    📚 314 citations🎯 RCR 7.06Top 5% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Purpose To study the impact of high-dose therapy (HDT) with autologous stem-cell support in patients with symptomatic multiple myeloma (MM) between the ages of 55 and 65 years. Patients and Methods One hundred ninety patients between 55 and 65 years old who had newly diagnosed stage II or III MM were randomly assigned to receive either conventional chemotherapy (CCT; ie, monthly courses of a regimen of vincristine, melphalan, cyclophosphamide, and prednisone) or HDT and autologous blood stem-cell transplantation (using either melphalan alone 200 mg/m2 intravenous [IV] or melphalan 140 mg/m2 IV plus busulfan 16 mg/kg orally as pretransplantation cytoreduction). Results Within a median follow-up of 120 months, median event-free survival (EFS) times were 25 and 19 months in the HDT and CCT groups, respectively. Median overall survival (OS) time was 47.8 months in the HDT group compared with 47.6 months in the CCT group. A trend to better EFS (P = .07) was observed in favor of HDT, whereas OS curves were not statistically different (P = .91). The period of time without symptoms, treatment, and treatment toxicity (TwiSTT) was significantly longer for the HDT patients than for the CCT patients (P = .03). Conclusion With a median follow-up time of approximately 10 years, this randomized trial confirmed a benefit of HDT in terms of EFS and TwiSTT but did not provide evidence for superiority of HDT over CCT in OS of patients aged 55 to 65 years with symptomatic newly diagnosed MM.

  • 2
    Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

    Arthritis and rheumatism · 2010

    📚 306 citations🎯 RCR 8.99Top 3% NIH
    Lire l'abstract Crossref ↓

    AbstractObjectiveA number of open‐label studies have suggested the potential benefit of rituximab (RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off‐trial patients with SLE seen in regular clinical practice.MethodsWe analyzed prospective data from the French AutoImmunity and Rituximab (AIR) registry, which includes data on patients with autoimmune disorders treated with RTX.ResultsOne hundred thirty‐six patients received treatment for SLE. The mean ± SD score on the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) was 11.3 ± 8.9 at baseline. Severe infections were noted in 12 patients (9%), corresponding to a rate of 6.6/100 patient‐years. Most severe infections occurred within the first 3 months after the last RTX infusion. Five patients died, due to severe infection (n = 3) or refractory autoimmune disease (n = 2). Overall response was observed in 80 of 113 patients (71%) by the SELENA–SLEDAI assessment. Efficacy did not differ significantly between patients receiving RTX monotherapy and those receiving concomitant immunosuppressive agents (who had higher baseline disease activity). Articular, cutaneous, renal, and hematologic improvements were noted in 72%, 70%, 74%, and 88% of patients, respectively. Among responders, 41% experienced a relapse of disease, with a response in 91% after retreatment with RTX.ConclusionData from the AIR registry show a satisfactory tolerance profile and clinical efficacy of RTX in patients with SLE. The contrasting results with those from recent RCTs leave open the question of the therapeutic use of RTX in SLE. Additional controlled studies with new designs are needed to define the place of RTX in the therapeutic arsenal for SLE.

  • 3
    COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

    The Lancet. Rheumatology · 2021

    📚 220 citations🎯 RCR 12.10Top 2% NIH🔓 Open Access📄 PDF gratuit ↗

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal25

▼

Biothérapies non-anti-TNF7

▼

Anti-TNF2

▼

Arthrite juvénile2

▼

Case report / série2

▼

csDMARDs2

▼

Lupus2

▼

Revue générale2

▼

Vascularites2

▼

Activité physique / Rééducation1

▼

Corticothérapie1

▼

Épidémiologie & registres1

▼

Essai clinique1

▼

IRM ostéo-articulaire1

▼

Lombalgie1

▼

Sjögren1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.